Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIC-1911 Monotherapy and with Sotorasib in KRAS G12C-Mutant NSCLC
NCT05374538Phase 1Terminated
- Sponsor
- VITRAC Therapeutics, LLC
- Start
- Nov 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAS-119 in non-small cell lung cancer (NSCLC), sponsored by VITRAC Therapeutics, LLC. Primary endpoint: Treatment Emergent Adverse Events at 9 months. Started Nov 2022; status: terminated.
02
Drugs
TAS-119
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05374538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05374538.